Payment & Shipping Terms:
|CAS:||35189-28-7||Appearance:||White Crystalline Solid|
|Melting Point:||216 ° C||MW:||369.50|
|MF:||C23H31NO3||Application:||It Is An Important Raw Material|
legal bodybuilding supplements,
bodybuilding supplements steroids
Norgestimate Bodybuilding Anabolic Steroids 35189-28-7 For Woman Health Care
Synonyms: D-(17A)-17-Acetoxy-13-ethyl-18, 19-dinorpregn-4-en-20-yn-3-oneoxime; Norgestimate powder; Norgestimate steroid
Molecular Weight: 369.50
Density: 1.221 g/cm3
Melting Point: 216 ° C
Boiling Point: 497.896 ° C at 760 mmHg
Flash Point: 254.919 ° C
Appearance: White crystalline solid
PackAge: According to the clients requirement
Application: It is an important raw material
Storage: Store in dry, dark and ventilated place.
Norgestimate is a form of progestin, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol (a female sex hormone that is involved in the development and maintenance of the female reproductive system), to treat the symptoms of menopause.
Norgestimate and ethinylestradiol are used as an oral contraceptive, indicated for the prevention of pregnancy in women.
Norgestimate/ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Mifepristone is used for:
Ending pregnancy in women who have been pregnant for 49 days (7 weeks) or less. It may be used with other medicines. If mifepristone does not work, surgery to end the pregnancy may be necessary.
Mifepristone is a synthetic steroide. It works by blocking a hormone (progesterone) necessary for pregnancy to continue.
How to use mifepristone:
Use mifepristone as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Mifepristone comes with an extra patient information sheet called a Medication Guide and a Patient Agreement. Read them carefully. Read them again each time you get mifepristone refilled.
Mifepristone is supplied by your health care provider and is not available at a pharmacy.
Mifepristone requires 3 visits to your health care provider.
On day 1 at your health care provider's office, you will read the Medication Guide and discuss the benefits and risks of using mifepristone to end your pregnancy. If you decide mifepristone is right for you, sign the Patient Agreement. After your physical exam, you will take 3 tablets of mifepristone.
On day 3 at your health care provider's office, if you are still pregnant, you will take 2 misoprostol tablets. Misoprostol may cause cramps, nausea, diarrhea, and other symptoms. Your health care provider may give you other medicines for these symptoms.
Around day 14 at your health care provider's office, you will return for an important follow-up visit. You must return about 14 days after you have taken mifepristone to be sure the pregnancy has ended. If the pregnancy has not ended, there is a chance of birth defects. Your health care provider will discuss with you your choices, including surgical abortion.
Grapefruit and grapefruit juice may increase the risk of side effects from mifepristone. Talk to your doctor before including grapefruit or grapefruit juice in your diet while taking mifepristone.
You must follow the dosing schedule as directed by your doctor. If you miss an appointment, contact your doctor immediately.
Formulations / Preparations:
Norgestimate is available commercially as a component of a combination tablet with ethinylestradiol.
(1) Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
(2) Oral contraceptives should not be used in women who currently have the following conditions: thrombophlebitis or thromboembolic disorders; a past history of deep vein thrombophlebitis or thromboembolic disorders; cerebral vascular or coronary artery disease (current or past history); valvular heart disease with complications; severe hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization; known or suspected carcinoma of the breast or personal history of breast cancer; carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; acute or chronic hepatocellular disease with abnormal liver function; hepatic adenomas or carcinomas; known or suspected pregnancy; hypersensitivity to any component of this product.
(3) The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes.
Other Estrogen Steroids:
|Product name||CAS number|
Thank you and welcome your inquiry!